Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of
late-onset Alzheimer disease (AD), with the APOE* ε 4 allele conferring an increased risk …
late-onset Alzheimer disease (AD), with the APOE* ε 4 allele conferring an increased risk …
Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies
KA Jellinger - Journal of neural transmission, 2018 - Springer
Dementia with Lewy bodies (DLB) and Parkinson's disease-dementia (PDD), although
sharing many clinical, neurochemical and morphological features, according to DSM-5, are …
sharing many clinical, neurochemical and morphological features, according to DSM-5, are …
APOE genotype regulates pathology and disease progression in synucleinopathy
Apolipoprotein E (APOE) ε4 genotype is associated with increased risk of dementia in
Parkinson's disease (PD), but the mechanism is not clear, because patients often have a …
Parkinson's disease (PD), but the mechanism is not clear, because patients often have a …
APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid
The apolipoprotein E (APOE) ε4 allele is the strongest genetic risk factor for late-onset
Alzheimer's disease mainly by driving amyloid-β pathology. Recently, APOE4 has also been …
Alzheimer's disease mainly by driving amyloid-β pathology. Recently, APOE4 has also been …
APOE from astrocytes restores Alzheimer's Aβ-pathology and DAM-like responses in APOE deficient microglia
P Preman, D Moechars, E Fertan, L Wolfs… - EMBO Molecular …, 2024 - embopress.org
The major genetic risk factor for Alzheimer's disease (AD), APOE4, accelerates beta-amyloid
(Aβ) plaque formation, but whether this is caused by APOE expressed in microglia or …
(Aβ) plaque formation, but whether this is caused by APOE expressed in microglia or …
[HTML][HTML] Cognitive heterogeneity in Parkinson's disease: A mechanistic view
Cognitive impairment occurs in most individuals with Parkinson's disease (PD), exacting a
high toll on patients, their caregivers, and the healthcare system. In this review, we begin by …
high toll on patients, their caregivers, and the healthcare system. In this review, we begin by …
Pathological influences on clinical heterogeneity in Lewy body diseases
ABSTRACT PD, PD with dementia, and dementia with Lewy bodies are clinical syndromes
characterized by the neuropathological accumulation of alpha‐synuclein in the CNS that …
characterized by the neuropathological accumulation of alpha‐synuclein in the CNS that …
[HTML][HTML] Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis
M Posavi, M Diaz-Ortiz, B Liu, CR Swanson… - PLoS …, 2019 - journals.plos.org
Background Parkinson's disease (PD) is a progressive neurodegenerative disease affecting
about 5 million people worldwide with no disease-modifying therapies. We sought blood …
about 5 million people worldwide with no disease-modifying therapies. We sought blood …
Mind the gaps: what we don't know about cognitive impairment in essential tremor
Introduction Although the hallmark feature of essential tremor (ET) is tremor, there is growing
appreciation that cognitive impairment also occurs, including increased prevalence of mild …
appreciation that cognitive impairment also occurs, including increased prevalence of mild …
Mining genetic and transcriptomic data using machine learning approaches in Parkinson's disease
High-throughput techniques have generated abundant genetic and transcriptomic data of
Parkinson's disease (PD) patients but data analysis approaches such as traditional …
Parkinson's disease (PD) patients but data analysis approaches such as traditional …